Skip to main content

Table 1 Baseline demographic characteristics

From: The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study

 

CASE group

(NPE development)

CONTROL group

(No NPE development)

P value

Sex

 Male

13,206 (41.4%)

13,221 (41.4%)

0.90

 Female

18,716 (58.6%)

18,701 (58.6%)

Age, mean (SD)

72.7 (6.6)

72.6 (6.6)

0.11

Age group

 60s

11,483 (36.0%)

11,459 (35.9%)

0.10

 70s

15,227 (47.7%)

15,440 (48.4%)

 80s

4824 (15.1%)

4619 (14.5%)

 90s

388 (1.2%)

404 (1.3%)

Income level

 Q0-Q2

8248 (25.8%)

8038 (25.2%)

0.11

 Q3-Q5

5465 (17.1%)

5643 (17.7%)

 Q6-Q8

8046 (25.2%)

8117 (25.4%)

 Q9-Q10

10,163 (31.8%)

10,124 (31.7%)

LTMA use

 Yes

3225 (10.1%)

2115 (6.6%)

< 0.01

 No

28,697 (89.9%)

29,807 (93.4%)

Comorbidities

 CCI score, mean (SD)

2.52 (2.14)

2.51 (2.19)

0.55

  Group 1 (0)

3320 (10.4%)

3489 (10.9%)

0.06

  Group 2 (2 ≥ cci ≥1)

16,161 (50.6%)

16,173 (50.7%)

  Group 3 (cci ≥ 3)

12,441 (39.0%)

12,260 (38.4%)

 Myocardial infarction

  Yes

971 (3.0%)

935 (2.9%)

0.40

  No

30,951 (97.0%)

30,987 (97.1%)

 Congestive heart failure

  Yes

3610 (11.3%)

3560 (11.1%)

0.53

  No

28,312 (88.7%)

28,362 (88.9%)

 Arrhythmia

  Yes

2131 (6.7%)

2070 (6.5%)

0.33

  No

29,791 (93.3%)

29,852 (93.5%)

 Hypertension

  Yes

19,563 (61.3%)

19,882 (62.3%)

< 0.01

  No

12,359 (38.7%)

12,040 (37.7%)

 Dyslipidemia

  Yes

9630 (30.2%)

9510 (29.8%)

0.30

  No

22,292 (69.8%)

22,412 (70.2%)

 Peripheral vascular disease

  Yes

5080 (15.9%)

4892 (15.3%)

0.04

  No

26,842 (84.1%)

27,030 (84.7%)

 Cerebrovascular disease

  Yes

5289 (16.6%)

5108 (16.0%)

0.05

  No

26,633 (83.4%)

26,814 (84.0%)

 Dementia

  Yes

1745 (5.5%)

1495 (4.7%)

< 0.01

  No

30,177 (94.5%)

30,427 (95.3%)

 Parkinson’s disease

  Yes

422 (1.3%)

374 (1.2%)

0.09

  No

31,500 (98.7%)

31,548 (98.8%)

 Chronic pulmonary disease

  Yes

19,022 (59.6%)

19,449 (60.9%)

< 0.01

  No

12,900 (40.4%)

12,473 (39.1%)

 Rheumatoid arthritis

  Yes

1779 (5.6%)

1789 (5.6%)

0.86

  No

30,143 (94.4%)

30,133 (94.4%)

 Peptic ulcer disease

  Yes

10,512 (32.9%)

10,402 (32.6%)

0.35

  No

21,410 (67.1%)

21,520 (67.4%)

 Liver disease

  Yes

6378 (20.0%)

6263 (19.6%)

0.25

  No

25,544 (80.0%)

25,659 (80.4%)

 Diabetes mellitus

  Yes

8547 (26.8%)

8434 (26.4%)

0.31

  No

23,375 (73.2%)

23,488 (73.6%)

 Hemiplegia or Paraplegia

  Yes

677 (2.1%)

640 (2.0%)

0.30

  No

31,245 (97.9%)

31,282 (98.0%)

 Renal disease

  Yes

644 (2.0%)

622 (2.0%)

0.53

  No

31,278 (98.0%)

31,300 (98.0%)

 Malignancy

  Yes

2915 (9.1%)

2938 (9.2%)

0.75

  No

29,007 (90.9%)

28,984 (90.8%)

 HIV

  Yes

3 (0.01%)

2 (0.02)

0.65

  No

31,919 (99.9%)

31,920 (99.99%)

  1. Abbreviations: NPE Neuropsyhciatric event, SD Standard Deviation, CCI Charlson Comorbidity Index, LTMA Leukotriene Modifying Agent, HIV Human Immunodeficiency Virus
  2. Chi-square test was used for categorical variables, t-test was used for numerical variables.